Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Medrysone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 8/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.71 |
| ▸ | HSD11B2 | P80365 | 3/20 | 0.70 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.70 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.70 |
| ▸ | TSHR | P16473 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | SHBG | P04278 | 3/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.56 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Medrysone SCHEMBL12998543 | 1.00 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2HIF1ACYP2C9LMNA | |
| Medrysone SCHEMBL3048275 | 1.00 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2HIF1ACYP2C9LMNA | |
| Medrysone SCHEMBL29866793 | 1.00 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2HIF1ACYP2C9LMNA | |
| Medrysone SCHEMBL13054978 | 1.00 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2HIF1ACYP2C9LMNA | |
| Medrysone SCHEMBL840781 | 0.96 | CYP3A4 (0.93) | CYP3A4SMN1; SMN2HIF1ACYP2C9LMNA | |
| SCHEMBL23975165 | 0.92 | CYP3A4 (0.85) | CYP3A4SMN1; SMN2HIF1ACYP2C9LMNA | |
| SCHEMBL8668291 | 0.89 | SMN1; SMN2 (0.80) | CYP3A4SMN1; SMN2HIF1ACYP2C9LMNA | |
| SCHEMBL8668298 | 0.89 | SMN1; SMN2 (0.80) | CYP3A4SMN1; SMN2HIF1ACYP2C9LMNA | |
| SCHEMBL6018287 | 0.87 | CYP3A4 (0.77) | CYP3A4SMN1; SMN2HIF1ACYP2C9LMNA | |
| SCHEMBL6018282 | 0.87 | CYP3A4 (0.77) | CYP3A4SMN1; SMN2HIF1ACYP2C9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 16394 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137657-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260139030-A1 | CHIMERIC PROTEINS FOR TREATING CUTANEOUS INFLAMMATION | SHATTUCK LABS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137656-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260103492-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2026-04-16 | — | — | US | claimed |
| EP-4724079-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-12569451-B2 | Bio-inspired tissue-adhesive hydrogel patch and uses thereof | Cellartgen Inc. (KR) | 2026-03-10 | — | — | US | claimed |
| EP-3717017-B1 | COVALENT ANESTHETIC-POLYMER CONJUGATES FOR PROLONGED LOCAL ANESTHESIA | CHILDRENS MEDICAL CT CORP (US) | 2026-02-25 | — | — | EP | claimed |
| US-20260048096-A1 | METHODS AND COMPOSITIONS FOR PRESERVING THE RETINAL OUTER NUCLEAR LAYER (ONL), PHOTORECEPTORS, AND RETINAL THICKNESS | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-02-19 | — | — | US | claimed |
| EP-4301343-B1 | PHARMACEUTICAL COMPOSITIONS WITH REDUCED SIDE EFFECT AND METHODS OF USING THE SAME | TLC BIOPHARMACEUTICALS INC (US) | 2025-11-19 | — | — | EP | claimed |
| US-12421281-B2 | Cyclosporine compositions and methods of use | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2025-09-23 | — | — | US | claimed |
| EP-0173478-A1 | Treatment of skin disorders | SCOTIA HOLDINGS PLC (GB) | 1986-03-05 | — | — | EP | claimed |
| EP-0126684-A2 | Drug delivery system utilizing thermosetting gels | MERCK & CO. INC. (US) | 1984-11-28 | — | — | EP | claimed |
| US-4474751-A | SUSTAINED RELEASE USING AN ALKYLENEDIAMINE-MODIFIED ETHYLENE OXIDE-PROPYLENE OXIDE COPOLYMER | MERCK & CO., INC. (US) | 1984-10-02 | — | — | US | claimed |
| US-4407792-A | HIGH MOLECULAR WEIGHT ETHYLENE-MALEIC ANHYDRIDE COPOLYMER | ALCON LABORATORIES, INC. (US) | 1983-10-04 | — | — | US | claimed |
| US-4271143-A | ACRYLIC POLYMER GEL | ALCON LABORATORIES, INC. (US) | 1981-06-02 | — | — | US | claimed |
| US-4186184-A | Selective administration of drug with ocular therapeutic system | ALZA CORPORATION (US) | 1980-01-29 | — | — | US | claimed |
| US-4016251-A | Vaginal drug dispensing device | ALZA CORPORATION (US) | 1977-04-05 | — | — | US | claimed |
| US-4014335-A | Ocular drug delivery device | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | claimed |
| US-4001388-A | POLYESTERS | ALZA CORPORATION (US) | 1977-01-04 | — | — | US | claimed |
| US-3962414-A | Structured bioerodible drug delivery device | ALZA CORPORATION (US) | 1976-06-08 | — | — | US | claimed |